Neuronetics Reports Q3 2026 Revenue Growth and Positive Adjusted EBITDA
Neuronetics (STIM) reported strong third-quarter 2026 financial results, highlighted by a 12.5% year-over-year increase in total revenue to $42.0 million. The company achieved a significant turnaround in profitability, reporting an adjusted EBITDA of $1.9 million compared to a loss of $4.7 million in the same period last year. This improvement was driven by operational efficiencies and a strategic shift toward capital equipment sales within its NeuroStar segment. The Greenbrook clinic business served as a primary growth driver, with revenue rising 20.1% to $26.2 million due to improved revenue cycle management. While the company noted a planned decrease in session-based revenue, gross margins expanded to 52.2%. Management also raised its full-year 2026 gross margin guidance and lowered its operating expense outlook, signaling improved fiscal discipline as they expand their sales force.
Tickers: $STIM
Topics: EBITDA Turnaround Financial Guidance Gross Margin Improvement Revenue Growth